Defining the critical hurdles in cancer immunotherapy

Fox, Bernhard A., Schendel, Dolores J., Butterfield, Lisa H., Aamdal, Steinar, Allison, James P., Ascierto, Paolo Antonio, Atkins, Michael B., Bartunkova, Jirina, Bergmann, Lothar, Berinstein, Neil, Bonorino, Cristina C., Borden, Ernest, Bramson, Jonathan L., Britten, Cedrik M., Cao, Xuetao, Carson, William E., Chang, Alfred E., Characiejus, Dainius, Choudhury, A. Raja, Coukos, George, de Gruijl, Tanja, Dillman, Robert O., Dolstra, Harry, Dranoff, Glenn, Durrant, Lindy G., Finke, James H., Galon, Jerome, Gollob, Jared A., Gouttefangeas, Cecile, Grizzi, Fabio, Guida, Michele, Hakansson, Leif, Hege, Kristen, Herberman, Ronald B., Hodi, F. Stephen, Hoos, Axel, Huber, Christoph, Hwu, Patrick, Imai, Kohzoh, Jaffee, Elizabeth M., Jenetzki, Sylvia, June, Carl H., Kalinski, Pawel, Kaufman, Howard L., Kawakami, Koji, Kawakami, Yutaka, Keilholtz, Ulrich, Khleif, Samir N., Kiessling, Rolf, Kotlan, Beatrix, Kroemer, Guido, Lapointe, Rejean, Levitsky, Hyam I., Lotze, Michael T., Maccalli, Cristina, Maio, Michele, Marschner, Jens-Peter, Mastrangelo, Michael J., Masucci, Giuseppe, Melero, Ignacio, Melief, Cornelius, Murphy, William J., Nelson, Brad, Nicolini, Andrea, Nisimura, Michael I., Odunsi, Kunle, Ohashi, Pamela S., O'Donnell-Tormy, Jill, Old, Lloyd, Ottensmeier, Christian, Papamichail, Michael, Parmiani, Giorgio, Pawelec, Graham, Proietti, Enrico, Qin, Shukui, Rees, Robert, Ribas, Antoni, Ridolfi, Ruggero, Ritter, Gerd, Rivoltini, Licia, Romero, Pedro J., Salem, Mohamed L., Scheper, Rik J., Seliger, Barbara, Sharma, Padmanee, Shiku, Hiroshi, Singh-Jasuja, Harpreet, Song, Wenru, Straten, Per Thor, Tahara, Hideaki, Tian, Zhigang, van Der Berg, Sjoerd H., van Hoegen, Paul, Wang, Ena, Welters, Marij J. P., Winter, Hauke, Withington, Tara, Wolchok, Jedd D., Xiao, Weihua, Zitvogel, Laurence, Zwierzina, Heinz, Marincola, Francesco M., Gajewski, Thomas F., Wigginton, Jon M. and Disis, Mary L. (2011) Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine, 9 1: . doi:10.1186/1479-5876-9-214

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Fox, Bernhard A.
Schendel, Dolores J.
Butterfield, Lisa H.
Aamdal, Steinar
Allison, James P.
Ascierto, Paolo Antonio
Atkins, Michael B.
Bartunkova, Jirina
Bergmann, Lothar
Berinstein, Neil
Bonorino, Cristina C.
Borden, Ernest
Bramson, Jonathan L.
Britten, Cedrik M.
Cao, Xuetao
Carson, William E.
Chang, Alfred E.
Characiejus, Dainius
Choudhury, A. Raja
Coukos, George
de Gruijl, Tanja
Dillman, Robert O.
Dolstra, Harry
Dranoff, Glenn
Durrant, Lindy G.
Finke, James H.
Galon, Jerome
Gollob, Jared A.
Gouttefangeas, Cecile
Grizzi, Fabio
Guida, Michele
Hakansson, Leif
Hege, Kristen
Herberman, Ronald B.
Hodi, F. Stephen
Hoos, Axel
Huber, Christoph
Hwu, Patrick
Imai, Kohzoh
Jaffee, Elizabeth M.
Jenetzki, Sylvia
June, Carl H.
Kalinski, Pawel
Kaufman, Howard L.
Kawakami, Koji
Kawakami, Yutaka
Keilholtz, Ulrich
Khleif, Samir N.
Kiessling, Rolf
Kotlan, Beatrix
Kroemer, Guido
Lapointe, Rejean
Levitsky, Hyam I.
Lotze, Michael T.
Maccalli, Cristina
Maio, Michele
Marschner, Jens-Peter
Mastrangelo, Michael J.
Masucci, Giuseppe
Melero, Ignacio
Melief, Cornelius
Murphy, William J.
Nelson, Brad
Nicolini, Andrea
Nisimura, Michael I.
Odunsi, Kunle
Ohashi, Pamela S.
O'Donnell-Tormy, Jill
Old, Lloyd
Ottensmeier, Christian
Papamichail, Michael
Parmiani, Giorgio
Pawelec, Graham
Proietti, Enrico
Qin, Shukui
Rees, Robert
Ribas, Antoni
Ridolfi, Ruggero
Ritter, Gerd
Rivoltini, Licia
Romero, Pedro J.
Salem, Mohamed L.
Scheper, Rik J.
Seliger, Barbara
Sharma, Padmanee
Shiku, Hiroshi
Singh-Jasuja, Harpreet
Song, Wenru
Straten, Per Thor
Tahara, Hideaki
Tian, Zhigang
van Der Berg, Sjoerd H.
van Hoegen, Paul
Wang, Ena
Welters, Marij J. P.
Winter, Hauke
Withington, Tara
Wolchok, Jedd D.
Xiao, Weihua
Zitvogel, Laurence
Zwierzina, Heinz
Marincola, Francesco M.
Gajewski, Thomas F.
Wigginton, Jon M.
Disis, Mary L.
Title Defining the critical hurdles in cancer immunotherapy
Journal name Journal of Translational Medicine   Check publisher's open access policy
ISSN 1479-5876
Publication date 2011-12
Sub-type Article (original research)
DOI 10.1186/1479-5876-9-214
Open Access Status DOI
Volume 9
Issue 1
Total pages 13
Place of publication London, United Kingdom
Publisher BioMed Central
Collection year 2012
Language eng
Abstract Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strategies need to move into early stage clinical trials as quickly as it is safe, and if successful, these therapies should efficiently obtain regulatory approval and widespread clinical application. In late 2009 and 2010 the Society for Immunotherapy of Cancer (SITC), convened an “Immunotherapy Summit” with representatives from immunotherapy organizations representing Europe, Japan, China and North America to discuss collaborations to improve development and delivery of cancer immunotherapy. One of the concepts raised by SITC and defined as critical by all parties was the need to identify hurdles that impede effective translation of cancer immunotherapy. With consensus on these hurdles, international working groups could be developed to make recommendations vetted by the participating organizations. These recommendations could then be considered by regulatory bodies, governmental and private funding agencies, pharmaceutical companies and academic institutions to facilitate changes necessary to accelerate clinical translation of novel immune-based cancer therapies. The critical hurdles identified by representatives of the collaborating organizations, now organized as the World Immunotherapy Council, are presented and discussed in this report. Some of the identified hurdles impede all investigators; others hinder investigators only in certain regions or institutions or are more relevant to specific types of immunotherapy or first-in-humans studies. Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer.
Keyword Lymphocyte-associated antigen-4
T-cell responses
Metastatic melanoma
Translational research
Q-Index Code CX
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes Commentary

Document type: Journal Article
Sub-type: Article (original research)
Collections: Non HERDC
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 75 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 86 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 21 May 2012, 22:19:35 EST by System User on behalf of School of Medicine